Mmekorita:

Ụdị akụ:

ndabere onye mmekọ:

Nkọwa mmekọrịta:

Mmekorita:

Ụdị akụ:

Immuno-Oncology

ndabere onye mmekọ:

Yuhan Corporation bụ otu n'ime nnukwu ụlọ ọrụ na-emepụta ọgwụ na Korea, tọrọ ntọala ihe karịrị afọ 80 gara aga

Nkọwa mmekọrịta:

Joint Venture aha ya bụ ImmuneOncia Therapeutics, LLC

E lekwasịrị anya n'ịzụlite na ịzụ ahịa ọtụtụ ọgwụ mgbochi mgbochi mgbochi maka ọrịa hematological na etuto siri ike.

Mmekorita:

Ụdị akụ:

Immuno-Oncology

ndabere onye mmekọ:

Lee's Pharm bụ ụlọ ọrụ biopharma ọha na-arụ ọrụ ihe karịrị afọ 20 na China ma na-ere ngwaahịa 14 ugbu a na PRC.

Nkọwa mmekọrịta:

Sorrento enyela ikike pụrụiche nke Lee's Pharm ịzụlite na ịzụ ahịa ihe mgbochi mmadụ zuru oke maka PD-L1 mAb STI-A1014 maka nnukwu ahịa ndị China.

Mmekorita:

Ụdị akụ:

Usoro ọgwụgwọ cellular

ndabere onye mmekọ:

Celularity bụ mgbapụ sitere na Celgene Corporation na-elekwasị anya na ọgwụgwọ mkpụrụ ndụ sitere na placenta na eriri-ọbara.

Nkọwa mmekọrịta:

Equity Investment and Board nnọchiteanya

Mmekorita:

Ụdị akụ:

Immuno-oncology

ndabere onye mmekọ:

MABPHARM bụ ụlọ ọrụ biopharma na-elekwasị anya na R & D na mmepụta nke ọgwụ ọhụrụ na "Biobetters" maka ọrịa cancer na ọrịa autoimmune.

Nkọwa mmekọrịta:

Sorrento nwere ikike pụrụiche iji zụọ ahịa Biobetter anọ gụchara ọmụmụ ihe nke atọ na China maka ahịa North America, Europe na Japan.